FNCH — Finch Therapeutics Share Price
Last trade - 00:00- $2.20m
- -$18.56m
- $0.11m
- 26
- 56
- 18
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.11 | ||
| Price to Tang. Book | 0.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.34% | ||
| Return on Equity | -62.64% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.15 | 7.72 | 18.53 | 0.86 | 0.11 | n/a | 88.5 | -67.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Directors
- Christopher Shumway NEC (55)
- Mark Smith PRE (34)
- Andrew Noh CFD
- Gregory Perry CFO (60)
- Marc Blaustein COO (58)
- Howard Franklin SVP
- Bryan Gillis CTO
- Michelle Rose EXO
- Alka Batycky OTH
- Zain Kassam OTH (39)
- Joseph Vittiglio OTH (49)
- Domenic Ferrante IND (55)
- Nicholas Haft IND (32)
- Samuel Hamood IND
- Christian Lange IND (41)
- Jeffery Smisek IND (66)
- Jo Viney IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 21st, 2017
- Public Since
- March 19th, 2021
- No. of Shareholders
- 66
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,605,763
- Address
- 75 State Street, Suite 100, BOSTON, 02109
- Web
- https://finchtherapeutics.com/
- Phone
- +1 6172296499
- Auditors
- Deloitte & Touche LLP
Upcoming Events for FNCH
Similar to FNCH
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 24:20 UTC, shares in Finch Therapeutics are trading at $1.33. This share price information is delayed by 15 minutes.
Shares in Finch Therapeutics last closed at $1.33 and the price had moved by -84.24% over the past 365 days. In terms of relative price strength the Finch Therapeutics share price has underperformed the S&P500 Index by -86.77% over the past year.
The overall consensus recommendation for Finch Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Finch Therapeutics does not currently pay a dividend.
Finch Therapeutics does not currently pay a dividend.
Finch Therapeutics does not currently pay a dividend.
To buy shares in Finch Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.33, shares in Finch Therapeutics had a market capitalisation of $2.14m.
Here are the trading details for Finch Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: FNCH
Based on an overall assessment of its quality, value and momentum Finch Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Finch Therapeutics is $90.00. That is 6666.92% above the last closing price of $1.33.
Analysts covering Finch Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$20.59 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Finch Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -66.17%.
As of the last closing price of $1.33, shares in Finch Therapeutics were trading -58.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Finch Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Finch Therapeutics' management team is headed by:
- Christopher Shumway - NEC
- Mark Smith - PRE
- Andrew Noh - CFD
- Gregory Perry - CFO
- Marc Blaustein - COO
- Howard Franklin - SVP
- Bryan Gillis - CTO
- Michelle Rose - EXO
- Alka Batycky - OTH
- Zain Kassam - OTH
- Joseph Vittiglio - OTH
- Domenic Ferrante - IND
- Nicholas Haft - IND
- Samuel Hamood - IND
- Christian Lange - IND
- Jeffery Smisek - IND
- Jo Viney - IND